Haizheng Pharmaceutical (600267.SH) subsidiary's pharmaceutical product, fludarabine phosphate injection, was approved by the US FDA

Zhitong Finance App News, Haizheng Pharmaceutical (600267.SH) issued an announcement. Recently, Haizheng Pharmaceutical (Hangzhou) Co., Ltd. (“Haizheng Hangzhou Company”), a wholly-owned subsidiary of the company, received a notice from the US Food and Drug Administration (“US FDA”). Haizheng Hangzhou's New Drug Application (ANDA, or US Generic Drug Application) declared to the US FDA has been approved, which means Haizheng Hangzhou can sell this product in the US market.

According to reports, fludarabine phosphate injection is a nucleoside metabolism inhibitor. The indications are: as a component of a combination treatment plan to treat adult B-cell chronic lymphocytic leukemia (CLL); for adult B-cell chronic lymphocytic leukemia patients who have previously received at least 1 type of alkylating agent that is ineffective, or whose disease progresses during treatment.